Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Automated medicinal chemistry.

Marcus Koppitz1, Knut Eis

  • 1Schering AG, Medicinal Chemistry, 13342 Berlin, Germany. marcus.koopitz@schering.de

Drug Discovery Today
|May 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.

Cancer discovery·2025
Same author

Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.

Cell chemical biology·2024
Same author

Correction to "Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069".

Journal of medicinal chemistry·2022
Same author

Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.

Bioorganic & medicinal chemistry·2022
Same author

Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists <b>BAY-4931</b> and <b>BAY-0069</b>.

Journal of medicinal chemistry·2022
Same author

BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.

Journal of medicinal chemistry·2021

Automated medicinal chemistry emerged to solve drug discovery bottlenecks caused by high-throughput screening. This review details its evolution from combinatorial chemistry to current automated approaches.

Area of Science:

  • Drug Discovery
  • Medicinal Chemistry
  • Chemical Biology

Background:

  • High-throughput screening (HTS) in the 1980s created a demand for vast numbers of small molecules.
  • The initial bottleneck in drug discovery was the limited supply of diverse chemical compounds for screening.
  • Combinatorial chemistry arose as an early strategy to address this supply challenge.

Purpose of the Study:

  • To review the evolution of chemical synthesis strategies in drug discovery.
  • To examine the development of automated medicinal chemistry from its origins.
  • To provide an overview of the current state of automated medicinal chemistry.

Main Methods:

  • Literature review of key developments in chemical synthesis and automation.
  • Analysis of the transition from traditional combinatorial chemistry to modern automated platforms.

Related Experiment Videos

  • Synthesis of historical context and current trends in automated drug discovery.

    • Main Results:

    • Combinatorial chemistry represented an initial, significant advancement in compound library generation.
    • The field has evolved beyond basic combinatorial approaches into more sophisticated automated systems.
    • Automated medicinal chemistry now encompasses diverse techniques and applications.

    Conclusions:

    • Automated medicinal chemistry is a critical evolution addressing drug discovery challenges.
    • The field continues to advance, offering new possibilities for efficient compound synthesis.
    • Understanding this evolution is key to appreciating current drug discovery methodologies.